Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine
Clinical Endocrinology · 19.07.2026
DOI: 10.1111/cen.70180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 19.07.2026. Verfasst von Ignacio Fuentes und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Intermediate‐risk papillary thyroid carcinoma (PTC) accounts for 40%–60% of newly diagnosed PTC and comprises a heterogeneous group with variable recurrence risk. The benefit of postoperative radioactive iodine (RAI) remains uncertain.
Objectives
To describe features, response‐to‐therapy outcomes, and ATA 2025 recurrence‐risk redistribution in patients with ATA 2015 intermediate‐risk PTC managed without adjuvant RAI.
Design
Retrospective cohort study.
Methods
Adults (≥ 18 years) with ATA 2015 intermediate‐risk PTC treated with total thyroidectomy (TT) or thyroid lobectomy (TL), with/without lymph node dissection, and followed for ≥ 1 year were included. Omission of postoperative RAI was based on histopathology, cervical ultrasound (US), serum thyroglobulin (Tg), and anti‐thyroglobulin antibodies (TgAb) measured within 6 months postoperatively. TL patients required negative US. TT patients required negative US plus Tg < 1 ng/mL if TgAb‐negative, or stable/declining TgAb if positive. Response to therapy was assessed using ATA 2015 dynamic risk stratification and reassessed with ATA 2025 criteria.
Results
Ninety‐nine patients were included; 84 (84.8%) were women, the mean age was 40.2 ± 13.3 years, and the median follow‐up was 4.8 years. Microscopic extrathyroidal extension was present in 51 (51.5%), lymph node metastases in 37 (37.4%), and extranodal extension in 4 (4.0%). By ATA 2015, 67 (67.7%) had an excellent response and 32 (32.3%) an indeterminate response; no incomplete responses or structural recurrences occurred. ATA 2025 reclassified 3 (3.0%) as low risk, 39 (39.4%) as low‐intermediate, 52 (52.5%) as high‐intermediate, and 5 (5.1%) as high risk.
Conclusions
Selected intermediate‐risk PTC patients managed without adjuvant RAI had excellent mid‐term outcomes, supporting a risk‐adapted de‐escalation strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
- CETREN-UC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Department of Nuclear Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Department of Head and Neck Surgery, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Department of Radiology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Department of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
ORCID-Profile: Ignacio Fuentes, Marlín Solórzano, Annette Madison, Joaquín Viñambres, Rodolfo Cabello, Nicole Lustig, Lorena Mosso, Juan Carlos Quintana, Francisco Domínguez, Pablo H Montero, José M Domínguez
Zitieren
APA
Fuentes, I., Solórzano, M., Madison, A., Falcón, J., Ruiz, C., Viñambres, J., Cabello, R., Lustig, N., Mosso, L., Jaimovich, R., Quintana, J. C., Domínguez, F., González, H. E., Montero, P. H., Cruz, F., Solar, A., & Domínguez, J. M. (2026). Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine. Clinical Endocrinology. https://doi.org/10.1111/cen.70180
Vancouver
Fuentes I, Solórzano M, Madison A, Falcón J, Ruiz C, Viñambres J, et al. Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine. Clinical Endocrinology. 2026. doi:10.1111/cen.70180
BibTeX
@article{Fuentes2026,
author = {Fuentes, Ignacio and Solórzano, Marlín and Madison, Annette and Falcón, Joel and Ruiz, Catalina and Viñambres, Joaquín and Cabello, Rodolfo and Lustig, Nicole and Mosso, Lorena and Jaimovich, Rodrigo and Quintana, Juan Carlos and Domínguez, Francisco and González, Hernán E and Montero, Pablo H and Cruz, Francisco and Solar, Antonieta and Domínguez, José M},
title = {Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70180}
}
EUVIMED